Announces Expanded Multi-Year Software
Agreement with Lilly
Continued Focus in 2024 on Advancing Science
Underlying Platform, Driving Software Adoption and Progressing
Proprietary Pipeline
Schr�dinger, Inc. (Nasdaq: SDGR), Schr�dinger (Nasdaq: SDGR),
whose physics-based computational platform is transforming the way
therapeutics and materials are discovered, today provided an update
on its progress across the business and announced its development
and operational goals for 2024.
Today Schr�dinger announced an expanded, three-year, software
agreement with Eli Lilly and Company. The three-year agreement
builds on the collaboration established in 2022. The agreement
provides Lilly with large-scale access to Schr�dinger’s full suite
of technologies to enable and accelerate all stages of drug
discovery, from target enablement and assessment of target
druggability to hit discovery and lead optimization activities
through development candidate identification. Schr�dinger will
provide advanced support to ensure full integration and
optimization of the platform across Lilly’s research sites.
“We made important progress across the business in 2023, working
with Lilly and other companies to enable more discovery programs at
scale, expanding the capabilities of our platform, and increasing
our focus on our proprietary pipeline,1 which now includes two
clinical-stage development candidates,” stated Ramy Farid, Ph.D.,
chief executive officer at Schr�dinger. “We see continued
opportunities this year to grow our software business, progress a
third development candidate into the clinic, and advance our
ongoing clinical studies to enable data readouts from our first two
patient trials in late 2024 or 2025.”
“Our conviction about our own programs is increasing. We
continue to be selective about entering new collaborations, and we
will allocate more of our drug discovery resources to our
proprietary pipeline this year,” stated Geoff Porges, MBBS, chief
financial officer of Schr�dinger. “We expect our drug discovery
revenue in 2024 to be similar to or lower than 2022,2 reflecting
these changes in our strategic priorities and the strategic
decisions by certain partners to return programs in 2023. We
believe our increased focus on our proprietary pipeline creates
multiple paths for generating meaningful value in the coming
years.”
2023 Achievements
Today Schr�dinger highlighted several 2023 achievements:
Proprietary Pipeline
- Presented initial results from the healthy volunteer study of
SGR-1505, its MALT1 inhibitor
- Advanced the Phase 1 study of SGR-1505 in patients with
advanced B-cell malignancies, including expanding the study at
additional sites in the U.S. and Europe
- Received FDA orphan drug designation for SGR-1505 in mantle
cell lymphoma
- Received IND clearance for SGR-2921, its CDC7 inhibitor, and
initiated a Phase 1 study in patients with AML and MDS
- Advanced SGR-3515, its Wee1/Myt1 inhibitor, to development
candidate status and initiated IND-enabling activities
- Presented preclinical data for SGR-1505 and SGR-2921 at the
American Society of Hematology (ASH) Annual Meeting and for the
NLRP3 program at the Inflammasome Therapeutics Summit
- Progressed newly disclosed discovery programs, including
EGFRC797S, PRMT5-MTA and NLRP3 discovery programs
Platform
- Released new and major improvements to existing technologies,
including enabling the optimization of certain key ADMET
properties, the first full release of technology to predict
antibody affinity as a function of pH, software to more accurately
predict small molecule pKa values, and a computational approach to
identify brain penetrant molecules
- Published 21 peer-reviewed articles in life sciences and
materials science journals
Business
- Appointed Margaret Dugan, M.D., as chief medical officer to
lead clinical development and regulatory strategy for Schr�dinger’s
proprietary pipeline
- Strengthened balance sheet with $147.3M in cash distributions
from Nimbus’s sale of its TYK2 inhibitor to Takeda
- Renewed and expanded battery research agreement with Gates
Ventures for second three-year term
- Published inaugural corporate sustainability report
2024 Development and Operational Goals
Today Schr�dinger outlined the following development and
operational goals for 2024:
Development Goals
- Advance the Phase 1 study of SGR-1505 in advanced B cell
malignancies to enable initial data release in late 2024 or
2025
- Advance the Phase 1 study of SGR-2921 in patients with AML/MDS
to enable initial data release in late 2024 or 2025
- Submit the IND application for SGR-3515 in the first half of
2024 and initiate a Phase 1 study in 2024
- Advance the discovery-stage proprietary pipeline to enable an
additional IND submission in 2025
- Present additional data from proprietary programs in one or
more peer-reviewed forums
- Progress platform capabilities associated with biologics
- Publish research from the Gates battery research project
building on existing publications
Operational Goals
- Drive continued scale up and adoption of Schr�dinger’s software
platform across life sciences and materials science industries
- Generate positive returns from strategic investments of
Schr�dinger’s technology, expertise and capital
Schr�dinger will report its fourth quarter and full-year
financial results and provide 2024 financial guidance on Wednesday,
February 28, 2024, after the financial markets close. The company
will host a conference call and webcast at 4:30 p.m. ET.
About Schr�dinger
Schr�dinger is transforming the way therapeutics and materials
are discovered. Schr�dinger has pioneered a physics-based
computational platform that enables discovery of high-quality,
novel molecules for drug development and materials applications
more rapidly and at lower cost compared to traditional methods. The
software platform is licensed by biopharmaceutical and industrial
companies, academic institutions, and government laboratories
around the world. Schr�dinger’s multidisciplinary drug discovery
team also leverages the software platform to advance a portfolio of
collaborative and proprietary programs to address unmet medical
needs.
Founded in 1990, Schr�dinger has approximately 850 employees and
is engaged with customers and collaborators in more than 70
countries. To learn more, visit www.schrodinger.com, follow us on
LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, including but not limited to those regarding the potential
advantages of our computational platform, our research and
development efforts for our proprietary drug discovery programs and
our platform, the initiation, timing, progress, and results of our
proprietary drug discovery programs and the drug discovery programs
of our collaborators, the clinical potential and favorable
properties of our CDC7, MALT1, and Wee1/Myt1 inhibitors, including
SGR-1505, SGR-2921, SGR-3515, and other compounds discovered with
our platform, the timing of potential IND submissions as well as
initiation of, and reporting results from, clinical trials for our
proprietary drug discovery programs, the clinical potential and
favorable properties of our collaborators’ product candidates, our
expectations relating to our drug discovery revenue for the fiscal
year ending December 31, 2024, our ability to realize milestones,
royalties, and other payments from our collaborative and
proprietary programs, our plans to discover and develop product
candidates and to maximize their commercial potential by advancing
such product candidates ourselves or in collaboration with others,
our plans to leverage the synergies between our businesses, and our
progress towards achieving our strategic priorities are
forward-looking statements. Statements including words such as
“aim,” "anticipate," "believe," "contemplate," "continue," "could,"
"estimate," "expect," “goal,” "intend," "may," "might," "plan,"
"potential," "predict," "project," "should," "target," "will,"
"would" and statements in the future tense are forward-looking
statements. These forward-looking statements reflect our current
views about our plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to us and on assumptions we have made. Actual results may differ
materially from those described in the forward-looking statements
and are subject to a variety of assumptions, uncertainties, risks
and factors that are beyond our control, including the demand for
our software solutions, our ability to further develop our
computational platform, our reliance upon our third-party drug
discovery collaborators, the uncertainties inherent in drug
development and commercialization, such as the conduct of research
activities and the timing of and our ability to initiate and
complete preclinical studies and clinical trials, whether results
from preclinical and early clinical studies will be predictive of
results of later preclinical studies and clinical trials,
uncertainties associated with the regulatory review of clinical
trials and applications for marketing approvals, the ability to
retain and hire key personnel and other risks detailed under the
caption "Risk Factors" and elsewhere in our Securities and Exchange
Commission filings and reports, including our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission on
November 1, 2023, as well as future filings and reports by us. Any
forward-looking statements contained in this press release speak
only as of the date hereof. Except as required by law, we undertake
no duty or obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events, changes in expectations or otherwise.
Footnotes
1The company refers to its wholly-owned drug discovery programs
as its proprietary drug discovery pipeline and programs advanced by
or with the company’s collaborators as its collaborative
programs.
2The company reported $45.4 million in drug discovery revenue
for the fiscal year ended December 31, 2022.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240108954850/en/
Matthew Luchini (investors) Schr�dinger, Inc.
matthew.luchini@schrodinger.com 917-719-0636
Allie Nicodemo (Media) Schr�dinger, Inc.
allie.nicodemo@schrodinger.com 617-356-2325
Schrodinger (NASDAQ:SDGR)
過去 株価チャート
から 4 2024 まで 5 2024
Schrodinger (NASDAQ:SDGR)
過去 株価チャート
から 5 2023 まで 5 2024